MRNA Stock Up 1.32% Now, Moderna Proceeds for Phase 2 Testing of Coronavirus Vaccine

Coinspeaker
MRNA Stock Up 1.32% Now, Moderna Proceeds for Phase 2 Testing of Coronavirus Vaccine

Moderna Inc proceeds ahead for the Phase 2 clinical trial of its vaccine to fight with the coronavirus. The company has received a nod from the Food and Drug Administration to proceed ahead with the project. MRNA stock is in the green in the pre-market.

MRNA Stock Up 1.32% Now, Moderna Proceeds for Phase 2 Testing of Coronavirus Vaccine

Coinspeaker

11 total views, 1 views today

Author: toutiao